TY - JOUR
T1 - Transforming growth factor β induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton
AU - Wang, Shizhen Emily
AU - Xiang, Bin
AU - Zent, Roy
AU - Quaranta, Vito
AU - Pozzi, Ambra
AU - Arteaga, Carlos L.
PY - 2009/1/15
Y1 - 2009/1/15
N2 - It has been proposed that cross talk between integrin and growth factor receptor signaling such as ErbB2 (HER2) is required for activation of downstream effectors and ErbB2-mediated mammary tumorigenes is. Here we show that transforming growth factor β (TGF-β) induced focal adhesion kinase (FAK)-dependent clustering of HER2 and integrins α6, β1, and β4 in HER2-overexpressing mammary epithelial cells without altering the total and surface levels of HER2 receptors. This effect was mediated by ligand-induced epidermal growth factor receptor (EGFR) activation and the subsequent phosphorylation of Src and FAK. We have previously reported that TGF-β up-regulates EGFR ligand shedding through a mechanism involving the phosphorylation of tumor necrosis factor-α-converting enzyme (TACE/ADAM17). Knockdown of TACE, FAK, or integrin α6 by siRNA or inhibition of EGFR or Src by specific inhibitors abrogated TGF-β-induced receptor clustering and signaling to phosphatidylinositol 3-kinase-Akt. Finally, inhibition of Src-FAK reversed TGF-β-induced resistance to the therapeutic HER2 inhibitor trastuzumab in HER2-overexpressing breast cancer cells. Taken together, these data suggest that, by activating Src-FAK, TGF-β integrates ErbB receptor and integrin signaling to induce cell migration and survival during breast cancer progression.
AB - It has been proposed that cross talk between integrin and growth factor receptor signaling such as ErbB2 (HER2) is required for activation of downstream effectors and ErbB2-mediated mammary tumorigenes is. Here we show that transforming growth factor β (TGF-β) induced focal adhesion kinase (FAK)-dependent clustering of HER2 and integrins α6, β1, and β4 in HER2-overexpressing mammary epithelial cells without altering the total and surface levels of HER2 receptors. This effect was mediated by ligand-induced epidermal growth factor receptor (EGFR) activation and the subsequent phosphorylation of Src and FAK. We have previously reported that TGF-β up-regulates EGFR ligand shedding through a mechanism involving the phosphorylation of tumor necrosis factor-α-converting enzyme (TACE/ADAM17). Knockdown of TACE, FAK, or integrin α6 by siRNA or inhibition of EGFR or Src by specific inhibitors abrogated TGF-β-induced receptor clustering and signaling to phosphatidylinositol 3-kinase-Akt. Finally, inhibition of Src-FAK reversed TGF-β-induced resistance to the therapeutic HER2 inhibitor trastuzumab in HER2-overexpressing breast cancer cells. Taken together, these data suggest that, by activating Src-FAK, TGF-β integrates ErbB receptor and integrin signaling to induce cell migration and survival during breast cancer progression.
UR - http://www.scopus.com/inward/record.url?scp=58349117913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58349117913&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-08-2649
DO - 10.1158/0008-5472.CAN-08-2649
M3 - Article
C2 - 19147560
AN - SCOPUS:58349117913
SN - 0008-5472
VL - 69
SP - 475
EP - 482
JO - Cancer Research
JF - Cancer Research
IS - 2
ER -